Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue

Oncotarget

Volumn 7, Issue 36, 2016, Pages 58649-58658

  Longo, Vito ^a   Brunetti, Oronzo ^b   Gnoni, Antonio ^c   Cascinu, Stefano ^d   Gasparini, Giampietro ^b   Lorusso, Vito ^b   Ribatti, Domenico ^b,e   Silvestris, Nicola ^b  

^a Hospital of Taranto   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^c ENT Department   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Angiogenesis; Desmoplastic reaction; Hypoxia; Pancreatic ductal adenocarcinoma

Indexed keywords

AFLIBERCEPT; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; ELPAMOTIDE; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; PACLITAXEL; PLACEBO; RAMUCIRUMAB; SORAFENIB; SUNITINIB; ANGIOGENESIS INHIBITOR;

ANTIANGIOGENIC THERAPY; BIOACCUMULATION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DIARRHEA; DISTANT METASTASIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; EXTRACELLULAR MATRIX; GENE FUNCTION; HUMAN; HYPOXEMIA; LIVER TOXICITY; NAUSEA; NEUROPATHY; NONHUMAN; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREATITIS; REVIEW; SURVIVAL RATE; SURVIVAL TIME; THROMBOEMBOLISM; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; VOMITING; ANIMAL; DISEASE MODEL; HYPOXIA; INFLAMMATION; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PERFUSION; PROGNOSIS;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; EXTRACELLULAR MATRIX; HUMANS; HYPOXIA; INFLAMMATION; MICE; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; PERFUSION; PROGNOSIS; TUMOR MICROENVIRONMENT;

EID: 84988432078     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10765     Document Type: Review

References (70)

1. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012; 21(3): 418-29. doi: 10.1016/j.ccr.2012.01.007.
2. Büchler P, Reber HA, Büchler M, Shrinkante S, Büchler MW, Friess H, Semenza GL, Hines OJ. Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas. 2003; 26(1): 56-64.
3. Shibaji T, Nagao M, Ikeda N, Kanehiro H, Hisanaga M, Ko S, Fukumoto A, Nakajima Y. Prognostic significance of HIF-1 alpha overexpression in human pancreatic cancer. Anticancer Research. 2003;23(6C): 4721-4727.
4. Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, Feig C, Nakagawa T, Caldwell ME, Zecchini HI, Lolkema MP, Jiang P, Kultti A, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 2013; 62(1): 112-20. doi: 10.1136/gutjnl-2012-302529. Epub 2012 Mar 30.
5. Kindler HL1, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010; 28(22): 3617-22.
6. Itakura J, Ishiwata T, Friess H, Fujii H, Matsumoto Y, Büchler MW, Korc M. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res. 1997; 3(8): 1309-16.
7. Ikeda N, Adachi M, Taki T, Huang C, Hashida H, Takabayashi A, Sho M, Nakajima Y, Kanehiro H, Hisanaga M, Nakano H, Miyake M. Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer. 1999; 79(9-10): 1553-63.
8. Seo Y, Baba H, Fukuda T, Takashima M, Sugimachi K. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer. 2000; 88(10): 2239-45.
9. Niedergethmann M, Hildenbrand R, Wostbrock B, Hartel M, Sturm JW, Richter A, Post S. High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas. 2002; 25(2): 122-9.
10. Ammendola M, Sacco R, Marech I, Sammarco G, Zuccalà V, Luposella M, Patruno R, Giordano M, Ruggieri E, Zizzo N, Gadaleta CD, Ranieri G. Microvascular density and endothelial area correlate with Ki-67 proliferative index in surgically-treated pancreatic ductal adenocarcinoma patients. Oncol Lett. 2015; 10(2): 967-971. Epub 2015 May 27.
11. Armstrong T, Packham G, Murphy LB, Bateman AC, Conti JA, Fine DR, Johnson CD, Benyon RC, Iredale JP. Type I collagen promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2004; 10(21): 7427-37.
12. Mahadevan D, Von Hoff DD. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther. 2007; 6(4): 1186-97. Epub 2007 Apr 3.
13. Heinemann V, Reni M, Ychou M, Richel DJ, Macarulla T, Ducreux M. Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies. Cancer Treat Rev. 2014; 40(1): 118-28. doi: 10.1016/j.ctrv.2013.04.004. Epub 2013 Jul 9.
14. Erkan M, Reiser-Erkan C, Michalski CW, Deucker S, Sauliunaite D, Streit S, Esposito I, Friess H, Kleeff J. Cancer-stellate cell interactions perpetuate the hypoxiafibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia. 2009; 11(5):497-508.
15. Masamune A, Kikuta K, Watanabe T, Satoh K, Hirota M, Shimosegawa T. Hypoxia stimulates pancreatic stellate cells to induce fibrosis and angiogenesis in pancreatic cancer. Am J Physiol Gastrointest Liver Physiol. 2008; 295(4): G709-17. doi: 10.1152/ajpgi.90356.2008. Epub 2008 Jul 31.
16. Erickson LA, Highsmith WE Jr, Fei P, Zhang J. Targeting the hypoxia pathway to treat pancreatic cancer. Drug Des Devel Ther. 2015; 9: 2029-31. doi: 10.2147/DDDT.S80888.eCollection.2015.
17. Korc M. Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer. 2003 7;2:8.
18. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2006; 20(10):1218-49
19. Ribatti D. Mast cells in lymphomas. Crit Rev Oncol Hematol. 2016 May;101:207-12. doi: 10.1016/j.critrevonc.2016.03.016. Epub 2016 Mar 25.
20. Guidolin D, Marinaccio C, Tortorella C, Annese T, Ruggieri S, Finato N, Crivellato E, Ribatti D. Non-random spatial relationships between mast cells and microvessels in human endometrial carcinoma. Clin Exp Med. 2016 Feb 17.
21. Ribatti D, Finato N, Crivellato E, Guidolin D, Longo V, Mangieri D, Nico B, Vacca A, Beltrami CA. Angiogenesis and mast cells in human breast cancer sentinel lymph nodes with and without micrometastases. Histopathology. 2007; 51(6):837-42. Epub 2007 Oct 17.
22. Esposito I, Menicagli M, Funel N, Bergmann F, Boggi U, Mosca F, Bevilacqua G, Campani D. Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J Clin Pathol. 2004; 57(6):630-6.
23. Karamitopoulou E, Shoni M, Theoharides TC. Increased number of non-degranulated mast cells in pancreatic ductal adenocarcinoma but not in acute pancreatitis. Int J Immunopathol Pharmacol. 2014; 27(2): 213-20.
24. Strouch MJ, Cheon EC, Salabat MR, Krantz SB, Gounaris E, Melstrom LG, Dangi-Garimella S, Wang E, Munshi HG, Khazaie K, Bentrem DJ. Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. Clin Cancer Res. 2010; 16(8): 2257-65. doi: 10.1158/1078-0432.CCR-09-1230. Epub 2010 Apr 6.
25. Chang DZ, Ma Y, Ji B, Wang H, Deng D, Liu Y, Abbruzzese JL, Liu YJ, Logsdon CD, Hwu P. Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2011; 17(22): 7015-23. doi: 10.1158/1078-0432.CCR-11-0607. Epub 2011 Oct 5.
26. Theoharides TC et al. Mast cells and pancreatic cancer. N Engl J Med. 2008 Apr 24;358(17):1860-1. doi: 10.1056/NEJMcibr0801519.
27. de Souza Junior DA, Santana AC, da Silva EZ, Oliver C, Jamur MC. The Role of Mast Cell Specific Chymases and Tryptases in Tumor Angiogenesis. Biomed Res Int. 2015; 2015:142359. doi: 10.1155/2015/142359. Epub 2015 Jun 4.
28. Ammendola M, Sacco R, Sammarco G, Donato G, Zuccalà V, Luposella M, Patruno R, Marech I, Montemurro S, Zizzo N, Gadaleta CD, Ranieri G. Mast cells density positive to tryptase correlates with angiogenesis in pancreatic ductal adenocarcinoma patients having undergone surgery. Gastroenterol Res Pract. 2014; 2014:951957. doi: 10.1155/2014/951957. Epub 2014 Jun 4.
29. Ma Y, Hwang RF, Logsdon CD, Ullrich SE. Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer. Cancer Res. 2013; 73(13): 3927-37. doi: 10.1158/0008-5472.CAN-12-4479. Epub 2013 Apr 30.
30. Thomas H. Pancreatic cancer: Infiltrating macrophages support liver metastasis. Nat Rev Gastroenterol Hepatol. 2016 doi: 10.1038/nrgastro.2016.71.
31. Schmid MC, Avraamides CJ, Foubert P, Shaked Y, Kang SW, Kerbel RS, Varner JA. Combined blockade of integrin-α4β1 plus cytokines SDF-1α or IL-1β potently inhibits tumor inflammation and growth. Cancer Res. 2011; 71(22): 6965-75. doi: 10.1158/0008-5472.CAN-11-0588.
32. Wang X, Liu Y, Ren H, et al. Polymorphisms in the hypoxia-inducible factor-1α gene confer susceptibility to pancreatic cancer. Cancer Biol Ther. 2011; 12(5): 383-387.
33. Kobayashi H1, Lin PC.Angiopoietin/Tie2 signaling, tumor angiogenesis and inflammatory diseases. Front Biosci. 2005; 10: 666-74.
34. Craven KE, Gore J, Wilson JL, Korc M. Angiogenic gene signature in human pancreatic cancer correlates with TGFbeta and inflammatory transcriptomes. Oncotarget. 2016 ;7(1): 323-41. doi: 10.18632/oncotarget.6345.
35. Yasutome M, Gunn J, Korc M. Restoration of Smad4 in BxPC3 Pancreatic Cancer Cells Attenuates Proliferation without Altering Angiogenesis. Clin Exp Metastasis. 2005; 22: 461-473.
36. Brunetti O , Russo A, Scarpa A, Santini D, Reni M, Bittoni A, Azzariti A, Aprile G, Delcuratolo S, Signorile M, Gnoni A, Palermo L, Lorusso V, et al. MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets? Oncotarget. 2015; 6(27): 23323-41. doi: 10.18632/oncotarget.4492.
37. Mace TA, Collins AL, Wojci SE, Croce CM, Lesinski GB, Bloomston M. Hypoxia induces the overexpression of microRNA-21 in pancreatic cancer cells. J Surg Res. 2013; 184:855-86.
38. Sabatel C, Malvaux L, Bovy N, Deroanne C, Lambert V, Gonzalez ML, Colige A, Rakic JM, Noël A, Martial JA, Struman I. MicroRNA-21 exhibits antiangiogenic function by targeting RhoB expression in endothelial cells. PLoS One. 2011; 10;6(2):e16979.
39. Sicard F, Gayral M, Lulka H, Buscail L, Cordelier P. Targeting miR-21 for the therapy of pancreatic cancer. Mol Ther. 2013;21:986-94.
40. Li L , Li B , Chen D , Liu L , Huang C , Lu Z , Lun L , Wan X . miR139 and miR200c regulate pancreatic cancer endothelial cell migration and angiogenesis. Oncol Rep. 2015; 34(1): 518. doi: 10.3892/or.2015.3945. Epub 2015 May 4.
41. Luo J, Guo P, Matsuda K, Truong N, Lee A, Chun C, Cheng SY, Korc M. Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo, Int. J. Cancer. 2001; 92 (3):361-369.
42. Hoshida T, Sunamura M, Duda DG, Egawa S, Miyazaki S, Shineha R, Hamada H, Ohtani H, Satomi S, Matsuno S. Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble fit-1 vascular endothelial growth factor receptor, Pancreas. 2002; 25 (2): 111-121.
43. Fukasawa M, Korc M. Vascular endothelial growth factortrap suppresses tumorigenicity of multiple pancreatic cancer cell lines, Clin. Cancer Res. 2004; 10 (10): 3327-3332.
44. Nagaraju GP, Zhu S, Ko JE, Ashritha N, Kandimalla R, Snyder JP, Shoji M, El-Rayes BF. Antiangiogenic effects of a novel synthetic curcumin analogue in pancreatic cancer. Cancer Lett. 2015; 357(2): 557-65. doi: 10.1016/j.canlet.2014.12.007. Epub 2014 Dec 9.
45. Bai R, Ding T, Zhao J, Liu S, Zhang L, Lan X, Yu Y, Yin L. The effect of PI3K inhibitor LY294002 and gemcitabine hydrochloride combined with ionizing radiation on the formation of vasculogenic mimicry of Panc-1 cells in vitro and in vivo. Neoplasma. 2016; 63(1): 80-92. doi: 10.4149/neo_2016_010.
46. Guo JQ, Zheng QH, Chen H, Chen L, Xu JB, Chen MY, Lu D, Wang ZH, Tong HF, Lin S. Ginsenoside Rg3 inhibition of vasculogenic mimicry in pancreatic cancer through downregulation of VE-cadherin/EphA2/MMP9/MMP2 expression. Int J Oncol. 2014; 45(3): 1065-72. doi: 10.3892/ijo.2014.2500. Epub 2014 Jun 16.
47. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, Tuveson DA. Cancer Cell. 2005; 7: 469.
48. Olson P, Chu GC, Perry SR, et al. Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma. Proc Natl Acad Sci USA 2011;108:E1275e84.
49. Singh M, Lima A, Molina R, Hamilton P, Clermont AC, Devasthali V, Thompson JD, Cheng JH, Bou Reslan H, Ho CC, Cao TC, Lee CV, Nannini MA, et al. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol. 2010; 28: 585-593.
50. Bai X, Zhi X, Zhang Q, Liang F, Chen W, Liang C, Hu Q, Sun X, Zhuang Z, Liang T. Inhibition of protein phosphatase 2A sensitizes pancreatic cancer to chemotherapy by increasing drug perfusion via HIF-1α-VEGF mediated angiogenesis. Cancer Lett. 2014; 28;355(2): 281-7. doi: 10.1016/j.canlet.2014.09.048. Epub 2014 Oct 7.
51. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009; 324(5933):1457-61. doi: 10.1126/science.1171362. Epub 2009 May 21.
52. Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, Dekleva EN, Saunders T, Becerra CP, Tattersall IW, Westphalen CB, Kitajewski J, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014; 25(6): 735-47. doi: 10.1016/j.ccr.2014.04.021. Epub 2014 May 22.
53. Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heifari P, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014;25(6):719-34. doi: 10.1016/j.ccr.2014.04.005. Epub 2014 May 22.
54. Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, Taber DA, Karrison T, Dachman A, Stadler WM, Vokes EE. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.J Clin Oncol. 2005; 23(31): 8033-40.
55. Roberts AS, Campa MJ, Gottlin EB, Jiang C, Owzar K, Kindler HL, Venook AP, Goldberg RM, O'Reilly EM, Patz EF Jr. Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303). Cancer. 2012; 118(2):571-8.
56. Nixon AB1, Pang H, Starr MD, Friedman PN, Bertagnolli MM, Kindler HL, Goldberg RM, Venook AP, Hurwitz HI; Alliance for Clinical Trials In Oncology. Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res. 2013; 19(24): 6957-66. doi: 10.1158/1078-0432.CCR-13-0926. Epub 2013 Oct 4.
57. Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, Verslype C, Scheithauer W, Shang A, Cosaert J, Moore MJ. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009; 27: 2231-2237.
58. Kindler HL, Ioka T, Richel DJ, Bennouna J, Létourneau R, Okusaka T, Funakoshi A, Furuse J, Park YS, Ohkawa S, Springett GM, Wasan HS, Trask PC,.et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomized phase 3 study, Lancet Oncol. 2011; 12 (3): 256-262, doi:10.1016/S1470-2045(11)70004-3.
59. Gonçalves A, Gilabert M, François E, Dahan L, Perrier H, Lamy R, Re D, Largillier R, Gasmi M, Tchiknavorian X, Esterni B, Genre D, Moureau-Zabotto L, et al.BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer, Ann. Oncol. 2012; 23 (11): 2799-2805. doi:10.1093/annonc/mds135.
60. Rougier P, Riess H, Manges R, Karasek P, Humblet Y, Barone C, Santoro A, Assadourian S, Hatteville L, Philip PA. Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer, Eur. J. Cancer 2013; 49 (12): 2633-2642, doi:10.1016/j.ejca.2013.04.002.
61. Reni M, Cereda S, Milella M, Novarino A, Passardi A, Mambrini A, Di Lucca G, Aprile G, Belli C, Danova M, Bergamo F, Franceschi E, Fugazza C, et al. Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial. Eur J Cancer. 2013; 49(17): 3609-15. doi: 10.1016/j.ejca.2013.06.041. Epub 2013 Jul 27.
62. Bergmann L, Maute L, Heil G, Rüssel J, Weidmann E, Köberle D, Fuxius S, Weigang-Köhler K, Aulitzky WE, Wörmann B, Hartung G, Moritz B, Edler L, et al. A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Eur J Cancer. 2015; 51(1): 27-36. doi: 10.1016/j.ejca.2014.10.010. Epub 2014 Nov 5.
63. Yamaue H, Tsunoda T, Tani M, Miyazawa M, Yamao K, Mizuno N, Okusaka T, Ueno H, Boku N, Fukutomi A, Ishii H, Ohkawa S. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study, Cancer Sci. 106 (7) (2015) 883-890, doi:10.1111/cas.12674.
64. Gore J, Craven KE, Wilson JL, Cote GA, Cheng M, Nguyen HV, Cramer HM, Sherman S, Korc M, ref TCGATCGA data and patient-derived orthotopic xenografts highlight pancreatic cancer-associated angiogenesis. Oncotarget. 2015; 6(10):7504-21. doi: 10.18632/oncotarget.3233.
65. NCT02581215 Phase II Randomized Trial of FOLFIRINOX +/-Ramucirumab in Advanced Pancreatic Cancer(Available at: https://clinicaltrials.gov/ct2/show/NCT02581215).
66. Sunil R. Hingorani, William Proctor Harris, Tara Elisabeth Seery, Lei Zheng, Darren Sigal, Andrew Eugene Hendifar, Fadi S. Braiteh, Mark Zalupski, Ari David Baron, Nathan Bahary, Andrea Wang-Gillam, Noelle K. LoConte, Gregory M. Springett, Paul S. Ritch, Aram F. Hezel, Wen Wee Ma, Venu Gopal Bathini, Xionghua W. Wu, Ping Jiang and Andrea J. Bullock Journal of Clinical Oncology, 2016 Gastrointestinal Cancers Symposium (January 21-23, 2016). Vol 34, No 4_suppl (February 1 Supplement), 2016: 439 © 2016 American Society of Clinical Oncology.
67. NCT01839487: PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer (HALO-109-202). (Available at: https://clinicaltrials.gov/ct2/show/NCT01839487).
68. Ko AH1, LoConte N, Tempero MA, Walker EJ, Kate Kelley R, Lewis S, Chang WC, Kantoff E, Vannier MW, Catenacci DV, Venook AP, Kindler HL A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas. 2016; 45(3): 370-5.
69. Infinity Reports Update from Phase 2 Study of Saridegib Plus Gemcitabine in Patients with Metastatic Pancreatic Cancer (Available at: http://phx.corporate-ir.net/phoenix.zhtml?c=121941&p=irol-newsArticle&ID=1653550&highlight=).
70. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002; 87: 161-1.